China · State Administration for Market Regulation of China — antitrust (SAMR and provincial AMRs, samr.gov.cn) · Abuse of a dominant market position
上海上药第一生化药业有限公司等4家公司
Why it is here
State Administration for Market Regulation of China — antitrust (SAMR and provincial AMRs, samr.gov.cn) — abuse of a dominant market position (上海市市场监管局上海市市场监督管理局 · 沪市监反垄处〔2023〕202301401号; 沪市监反垄处〔2023〕202301402号 · 市场监管总局发布上海上药第一生化药业有限公司等4家公司滥用市场支配地位案行政处罚决定书), from 22 December 2023.
State Administration for Market Regulation of China — antitrust (SAMR and provincial AMRs, samr.gov.cn) — Abuse of a dominant market position.
Details
- Company
- 上海上药第一生化药业有限公司等4家公司
- Authority
- State Administration for Market Regulation of China — antitrust (SAMR and provincial AMRs, samr.gov.cn)
- Decision
- Abuse of a dominant market position
- Grounds and details, as published
- 上海市市场监管局上海市市场监督管理局 · 沪市监反垄处〔2023〕202301401号; 沪市监反垄处〔2023〕202301402号 · 市场监管总局发布上海上药第一生化药业有限公司等4家公司滥用市场支配地位案行政处罚决定书
- From
- 22 December 2023
- Until
- —
- Status
- End date not published
- Source
- https://www.samr.gov.cn/fldys/tzgg/xzcf/art/2023/art_849f776484c549ec80455c1e2ad4cc42.html
- Licence
- Public antitrust decisions published by the State Administration for Market Regulation of China (samr.gov.cn/fldys)
SourceState Administration for Market Regulation of China — antitrust (SAMR and provincial AMRs, samr.gov.cn) · Abuse of a dominant market position